ChemProt-3.0: a global chemical biology diseases mapping

ChemProt is a publicly available compilation of chemical-protein-disease annotation resources that enables the study of systems pharmacology for a small molecule across multiple layers of complexity from molecular to clinical levels. In this third version, ChemProt has been updated to more than 1.7 million compounds with 7.8 million bioactivity measurements for 19 504 proteins. Here, we report the implementation of global pharmacological heatmap, supporting a user-friendly navigation of chemogenomics space. This facilitates the visualization and selection of chemicals that share similar structural properties. In addition, the user has the possibility to search by compound, target, pathway, disease and clinical effect. Genetic variations associated to target proteins were integrated, making it possible to plan pharmacogenetic studies and to suggest human response variability to drug. Finally, Quantitative Structure–Activity Relationship models for 850 proteins having sufficient data were implemented, enabling secondary pharmacological profiling predictions from molecular structure. Database URL: http://potentia.cbs.dtu.dk/ChemProt/

[1]  M. DePamphilis,et al.  HUMAN DISEASE , 1957, The Ulster Medical Journal.

[2]  Astrid Nehlig,et al.  Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects , 1992, Brain Research Reviews.

[3]  Gapped BLAST and PSI-BLAST: A new , 1997 .

[4]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[5]  Gregory D. Schuler,et al.  Database resources of the National Center for Biotechnology Information: update , 2004, Nucleic acids research.

[6]  Bryan L Roth,et al.  Screening the receptorome to discover the molecular targets for plant-derived psychoactive compounds: a novel approach for CNS drug discovery. , 2004, Pharmacology & therapeutics.

[7]  B. Stockwell,et al.  Multicomponent therapeutics for networked systems , 2005, Nature Reviews Drug Discovery.

[8]  Peter Willett,et al.  Similarity-based virtual screening using 2D fingerprints. , 2006, Drug discovery today.

[9]  P. Sorger,et al.  Systems biology and combination therapy in the quest for clinical efficacy , 2006, Nature chemical biology.

[10]  Xin Wen,et al.  BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities , 2006, Nucleic Acids Res..

[11]  Pall I. Olason,et al.  A human phenome-interactome network of protein complexes implicated in genetic disorders , 2007, Nature Biotechnology.

[12]  Stefan Wetzel,et al.  The Scaffold Tree - Visualization of the Scaffold Universe by Hierarchical Scaffold Classification , 2007, J. Chem. Inf. Model..

[13]  A. Barabasi,et al.  The human disease network , 2007, Proceedings of the National Academy of Sciences.

[14]  D. Rognan.  Chemogenomic approaches to rational drug design , 2007, British journal of pharmacology.

[15]  J. Lehár,et al.  Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.

[16]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[17]  Tudor I. Oprea,et al.  hERG classification model based on a combination of support vector machine method and GRIND descriptors. , 2008, Molecular pharmaceutics.

[18]  Stefan Wetzel,et al.  Interactive exploration of chemical space with Scaffold Hunter. , 2009, Nature chemical biology.

[19]  Lincoln Stein,et al.  Reactome knowledgebase of human biological pathways and processes , 2008, Nucleic Acids Res..

[20]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[21]  P. Bork,et al.  A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.

[22]  Gisbert Schneider,et al.  Virtual screening: an endless staircase? , 2010, Nature Reviews Drug Discovery.

[23]  Sean Ekins,et al.  When pharmaceutical companies publish large datasets: an abundance of riches or fool's gold? , 2010, Drug discovery today.

[24]  María Martín,et al.  Ongoing and future developments at the Universal Protein Resource , 2010, Nucleic Acids Res..

[25]  Tsippi Iny Stein,et al.  In-silico human genomics with GeneCards , 2011, Human Genomics.

[26]  Michelle Whirl-Carrillo,et al.  From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. , 2011, Biomarkers in medicine.

[27]  Carol A. Bocchini,et al.  A new face and new challenges for Online Mendelian Inheritance in Man (OMIM®) , 2011, Human mutation.

[28]  Michael S Lajiness,et al.  Systems chemical biology and the Semantic Web: what they mean for the future of drug discovery research. , 2012, Drug discovery today.

[29]  Rachael P. Huntley,et al.  The UniProt-GO Annotation database in 2011 , 2011, Nucleic Acids Res..

[30]  Barend Mons,et al.  Open PHACTS: semantic interoperability for drug discovery. , 2012, Drug discovery today.

[31]  Dong Wang,et al.  The relationship between rational drug design and drug side effects , 2012, Briefings Bioinform..

[32]  Susumu Goto,et al.  KEGG for integration and interpretation of large-scale molecular data sets , 2011, Nucleic Acids Res..

[33]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[34]  Anne Morgat,et al.  UniPathway: a resource for the exploration and annotation of metabolic pathways , 2011, Nucleic Acids Res..

[35]  Tudor I. Oprea,et al.  The CARLSBAD Database: A Confederated Database of Chemical Bioactivities , 2013, Database J. Biol. Databases Curation.

[36]  Asher Mullard,et al.  European Lead Factory opens for business , 2013, Nature Reviews Drug Discovery.

[37]  Tudor I. Oprea,et al.  ChemProt-2.0: visual navigation in a disease chemical biology database , 2012, Nucleic Acids Res..

[38]  Nils M. Kriege,et al.  Visual Analysis of Biological Activity Data with Scaffold Hunter , 2013, Molecular informatics.

[39]  David S. Wishart,et al.  DrugBank 4.0: shedding new light on drug metabolism , 2013, Nucleic Acids Res..

[40]  Damian Szklarczyk,et al.  STITCH 4: integration of protein–chemical interactions with user data , 2013, Nucleic Acids Res..

[41]  Ronald Frank,et al.  EU-OPENSCREEN--a European infrastructure of open screening platforms for chemical biology. , 2014, ACS chemical biology.

[42]  Antony J. Williams,et al.  The Royal Society of Chemistry and the delivery of chemistry data repositories for the community , 2014, Journal of Computer-Aided Molecular Design.

[43]  Tudor I. Oprea,et al.  An Overview of the Challenges in Designing, Integrating, and Delivering BARD , 2014, Journal of biomolecular screening.

[44]  Joanna L. Sharman,et al.  The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands , 2013, Nucleic Acids Res..

[45]  Evan Bolton,et al.  Database resources of the National Center for Biotechnology Information , 2017, Nucleic Acids Res..